IDEAYA Biosciences Inc

IDYA

Company Profile

  • Business description

    IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

  • Contact

    5000 Shoreline Court
    Suite 300
    South San FranciscoCA94080
    USA

    T: +1 650 443-6209

    https://www.ideayabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    145

Stocks News & Analysis

stocks

Chip stock selloff deepens in Asia, extends to Europe and US

The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks

Downgrade for ASX listed fund manager as redemptions pile on

Persistent outflows erode earnings outlook.
stocks

Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?

Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,940.40100.001.13%
CAC 407,956.7022.000.28%
DAX 4025,622.61239.990.95%
Dow JONES (US)52,002.41175.28-0.34%
FTSE 10010,881.9041.550.38%
HKSE24,186.83124.110.52%
NASDAQ26,140.03572.99-2.14%
Nikkei 22565,324.29898.341.39%
NZX 50 Index13,753.7379.07-0.57%
S&P 5007,659.4484.62-1.09%
S&P/ASX 2008,806.7087.001.00%
SSE Composite Index3,716.288.810.24%

Market Movers